MPR Weekly Dose Podcast #228 — Xolair biosimilar approved; Furoscix indication expanded; Novel implant for rare eye disease; Lorundrostat trial data; Elevated benzene in acne treatments episode artwork

EPISODE · Mar 14, 2025 · 13 MIN

MPR Weekly Dose Podcast #228 — Xolair biosimilar approved; Furoscix indication expanded; Novel implant for rare eye disease; Lorundrostat trial data; Elevated benzene in acne treatments

from MPR Weekly Dose

First Xolair biosimilar approved, Wearable furosemide loop diuretic gains expanded indication; Implant approved for macular telangiectasia; Novel treatment shows promise in hypertension; And testing reveals high benzene levels in over-the-counter acne treatments.

Episode metadata supplied by the publisher feed · Published Mar 14, 2025

Embed this episode

Ready to play

MPR Weekly Dose Podcast #228 — Xolair biosimilar approved; Furoscix indication expanded; Novel implant for rare eye disease; Lorundrostat trial data; Elevated benzene in acne treatments

0:00 13:21

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 13 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on March 14, 2025.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!